Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    0.00 (0.00%)
Bid:
0.00
Ask:
540.00
Spread: 35.00 (6.931%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director Declaration

4 Feb 2025 07:05

RNS Number : 7439V
Tate & Lyle PLC
04 February 2025
 

4 February 2025

 

Tate & Lyle PLC

 

 

DIRECTOR DECLARATION

 

Notification regarding external directorships

 

In accordance with Listing Rule 6.4.6, Tate & Lyle PLC (the 'Company') announces that Nick Hampton, Chief Executive Officer, has notified the Company of the following changes to his non-executive directorships:

 

· He will retire as a non-executive director, and as the Senior Independent Director, of Great Portland Estates PLC from 3 April 2025 (having served on the Board since 2016).

 

· He has been appointed as a non-executive director of Severn Trent PLC with effect from 4 April 2025. Nick will serve on the Audit and Risk, Treasury, Remuneration and Nominations Committees and will become Senior Independent Director on 1 May 2025.

 

 

END

 

For more information contact:

 

For Tate & Lyle PLC

 

Investors and analysts

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

Email: tate@fticonsulting.com

 

About Tate & Lyle PLC:

 

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day. Through our leading expertise in sweetening, mouthfeel and fortification, we develop ingredients and solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 39 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2024, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2023, revenue for the enlarged Tate & Lyle Group would have been £2.25 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedInX (Twitter)Facebook or YouTube .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNVXLFBELLEBBQ
Date   Source Headline
10th Nov 20227:00 amRNSHalf-year Report
1st Nov 20223:15 pmRNSTotal Voting Rights
4th Oct 20228:25 amRNSCancellation of Preference Share Listing
3rd Oct 20222:45 pmRNSPref. share reduction effective & timetable update
29th Sep 20221:00 pmRNSTimetable update re. cancellation of pref. shares
14th Sep 202212:15 pmRNSHolding(s) in Company
13th Sep 20223:00 pmRNSCourt approval of cancellation of Pref. shares
10th Aug 20222:15 pmRNSDirector/PDMR Shareholding
4th Aug 20223:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20224:00 pmRNSHolding(s) in Company
28th Jul 20221:00 pmRNSUpdate on Preference Share Reduction Timetable
28th Jul 202212:45 pmRNSResult of AGM
15th Jul 20225:20 pmRNSDirector/PDMR Shareholding
1st Jul 202210:45 amRNSBlock listing Interim Review
1st Jul 202210:17 amRNSTotal Voting Rights
29th Jun 20224:25 pmRNSDirector/PDMR Shareholding
29th Jun 20224:00 pmRNSDirector/PDMR Shareholding
24th Jun 20224:15 pmRNSHolding(s) in Company
23rd Jun 20223:00 pmRNSHolding(s) in Company
21st Jun 20222:30 pmRNSAnnual Financial Report and Notice of Meeting 2022
17th Jun 20222:00 pmRNSHolding(s) in Company
15th Jun 20222:00 pmRNSHolding(s) in Company
15th Jun 20227:00 amRNSProposed Cancellation&Repayment Preference Shares
10th Jun 20222:00 pmRNSHolding(s) in Company
9th Jun 20227:06 amRNSAcquisition
9th Jun 20227:00 amRNSFinal Results
19th May 20225:00 pmRNSDirector/PDMR Shareholding
9th May 20222:23 pmRNSHolding(s) in Company
6th May 20222:46 pmRNSHolding(s) in Company
3rd May 20225:45 pmRNSHolding(s) in Company
3rd May 20228:01 amRNSShare Consolidation Effective Total Voting Rights
29th Apr 20223:15 pmRNSListing and Trading Application
26th Apr 20224:00 pmRNSResult of Meeting
13th Apr 20222:00 pmRNSHolding(s) in Company
7th Apr 20225:30 pmRNSHolding(s) in Company
7th Apr 202211:00 amRNSCirc re. special dividend and share consolidation
5th Apr 20224:00 pmRNSHolding(s) in Company
4th Apr 20224:00 pmRNSDirector/PDMR Shareholding
1st Apr 20222:15 pmRNSDisposal completion
1st Apr 20222:00 pmRNSTotal Voting Rights
31st Mar 20227:00 amRNSAcquisition
24th Mar 20222:00 pmRNSHolding(s) in Company
24th Mar 202211:00 amRNSDirectorate Change
21st Mar 20222:00 pmRNSHolding(s) in Company
18th Mar 20223:30 pmRNSHolding(s) in Company
10th Mar 20222:00 pmRNSHolding(s) in Company
9th Mar 20222:00 pmRNSHolding(s) in Company
1st Mar 20229:22 amRNSTotal Voting Rights
18th Feb 20222:00 pmRNSHolding(s) in Company
17th Feb 20222:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.